FI950508A0 - Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä - Google Patents

Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä

Info

Publication number
FI950508A0
FI950508A0 FI950508A FI950508A FI950508A0 FI 950508 A0 FI950508 A0 FI 950508A0 FI 950508 A FI950508 A FI 950508A FI 950508 A FI950508 A FI 950508A FI 950508 A0 FI950508 A0 FI 950508A0
Authority
FI
Finland
Prior art keywords
reverse transcriptase
benzoxazinones
hiv
inhibitors
hiv reverse
Prior art date
Application number
FI950508A
Other languages
English (en)
Swedish (sv)
Other versions
FI115457B (fi
FI950508A (fi
Inventor
Steven D Young
Susan F Britcher
Linda S Payne
Lekhanh O Tran
Jr William C Lumma
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI950508(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI950508A0 publication Critical patent/FI950508A0/fi
Publication of FI950508A publication Critical patent/FI950508A/fi
Application granted granted Critical
Publication of FI115457B publication Critical patent/FI115457B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI950508A 1992-08-07 1995-02-06 Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi FI115457B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US92660792 1992-08-07
US5480593A 1993-04-27 1993-04-27
US5480593 1993-04-27
PCT/US1993/007376 WO1994003440A1 (en) 1992-08-07 1993-08-06 Benzoxazinones as inhibitors of hiv reverse transcriptase
US9307376 1993-08-06

Publications (3)

Publication Number Publication Date
FI950508A0 true FI950508A0 (fi) 1995-02-06
FI950508A FI950508A (fi) 1995-02-06
FI115457B FI115457B (fi) 2005-05-13

Family

ID=26733517

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950508A FI115457B (fi) 1992-08-07 1995-02-06 Menetelmä farmaseuttisesti hyväksyttävien 6-kloori-4-trifluorimetyyli-1,4-dihydro-2H-3,1-bentsoksatsin-2-onijohdannaisten valmistamiseksi

Country Status (37)

Country Link
EP (1) EP0582455B1 (fi)
JP (1) JPH0780860B2 (fi)
KR (1) KR100272387B1 (fi)
CN (3) CN1318031C (fi)
AT (1) ATE197295T1 (fi)
AU (1) AU670300B2 (fi)
BG (1) BG62612B1 (fi)
CA (1) CA2101572C (fi)
CZ (1) CZ290447B6 (fi)
DE (4) DE10199013I2 (fi)
DK (1) DK0582455T3 (fi)
DZ (1) DZ1707A1 (fi)
ES (1) ES2151897T3 (fi)
FI (1) FI115457B (fi)
GR (1) GR3034754T3 (fi)
HK (1) HK1009267A1 (fi)
HR (1) HRP931102B1 (fi)
HU (1) HU223076B1 (fi)
IL (1) IL106507A (fi)
LU (2) LU90709I2 (fi)
LV (1) LV12719B (fi)
MX (1) MX192812B (fi)
MY (1) MY109834A (fi)
NL (2) NL300032I2 (fi)
NO (3) NO304886B1 (fi)
NZ (1) NZ255216A (fi)
PL (2) PL175615B1 (fi)
PT (1) PT582455E (fi)
RO (1) RO113641B1 (fi)
RU (1) RU2186775C2 (fi)
SG (1) SG52698A1 (fi)
SI (1) SI9300419B (fi)
SK (1) SK282276B6 (fi)
TW (2) TWI233436B (fi)
UA (1) UA42699C2 (fi)
WO (1) WO1994003440A1 (fi)
YU (1) YU49439B (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
CA2260922A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
CN1073991C (zh) * 1997-02-05 2001-10-31 麦克公司 使用抗溶剂的逆转录酶抑制剂结晶工艺
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
NZ500727A (en) * 1997-04-07 2001-06-29 Du Pont Pharm Co Preparation of benzoxazinones by adding acetonitrile and p-toluenesulfonic acid with heat
US6124302A (en) * 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
ATE253548T1 (de) * 1997-09-03 2003-11-15 Merck & Co Inc Verfahren zur verbesserung der optischen reinheit von 2r-(1-hydroxy-1-trifluormethyl-3- cyclopropylpropyn-2-yl)-4-chloranilin
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
CA2333643A1 (en) * 1998-06-30 2000-01-06 James D. Rodgers Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002081456A1 (en) 2001-03-28 2002-10-17 Bristol-Myers Squibb Company Cyanamide, alkoxyamino, and urea derivatives of 4, 4-disubstituted-3, 4-dihydro-2 (1h)- quinazolinones as hiv reverse transcriptase inhibitors
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
CA2701406C (en) * 2007-10-05 2016-01-26 Banyu Pharmaceutical Co., Ltd. Benzoxazinone derivative
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2011000532A2 (de) 2009-07-03 2011-01-06 Archimica Gmbh Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103664816B (zh) * 2011-01-06 2016-03-02 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
JP7071036B2 (ja) 2019-02-15 2022-05-18 福建永晶科技股▲ふん▼有限公司 Ｆｒｉｅｄｅｌ－Ｃｒａｆｔｓ反応の新しい新方法及び当該方法に用いられる触媒
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
WO2023064196A1 (en) * 2021-10-15 2023-04-20 Merck Sharp & Dohme Llc Benzoxazinone derivatives as selective cytotoxic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
FI115457B (fi) 2005-05-13
YU53093A (sh) 1996-10-09
HUT71219A (en) 1995-11-28
SK16195A3 (en) 1995-07-11
SI9300419B (sl) 2002-10-31
IL106507A (en) 1997-11-20
JPH0780860B2 (ja) 1995-08-30
MY109834A (en) 1997-08-30
PL175615B1 (pl) 1999-01-29
LV12719B (lv) 2001-12-20
NO950424L (no) 1995-04-06
YU49439B (sh) 2006-03-03
EP0582455A1 (en) 1994-02-09
TWI233436B (en) 2005-06-01
PL307348A1 (en) 1995-05-15
HU9500366D0 (en) 1995-03-28
NO304886B1 (no) 1999-03-01
AU670300B2 (en) 1996-07-11
CA2101572A1 (en) 1994-02-08
KR100272387B1 (ko) 2000-11-15
CN1221608A (zh) 1999-07-07
GR3034754T3 (en) 2001-02-28
CN1250652A (zh) 2000-04-19
ES2151897T3 (es) 2001-01-16
SK282276B6 (sk) 2002-01-07
HU223076B1 (hu) 2004-03-01
UA42699C2 (uk) 2001-11-15
KR950702970A (ko) 1995-08-23
HK1009267A1 (en) 1999-05-28
MX192812B (es) 1999-07-30
DZ1707A1 (fr) 2002-02-17
RU95107403A (ru) 1996-11-20
NO2008008I1 (no) 2008-06-30
CN1051767C (zh) 2000-04-26
TW382014B (en) 2000-02-11
NL300347I1 (nl) 2008-07-01
CZ28695A3 (en) 1995-09-13
DE69329608T2 (de) 2001-05-03
DK0582455T3 (da) 2000-11-27
NL300032I2 (nl) 2001-04-02
PL176679B1 (pl) 1999-07-30
CA2101572C (en) 2001-08-28
BG99383A (bg) 1995-09-29
DE69329608D1 (de) 2000-12-07
MX9304775A (es) 1994-05-31
FI950508A (fi) 1995-02-06
IL106507A0 (en) 1993-11-15
CN1318031C (zh) 2007-05-30
HRP931102B1 (en) 2001-06-30
NO2000004I1 (no) 2000-06-16
RU2186775C2 (ru) 2002-08-10
SI9300419A (en) 1994-06-30
AU4449693A (en) 1994-02-10
NO950424D0 (no) 1995-02-06
DE10199013I2 (de) 2007-05-24
CN1090277A (zh) 1994-08-03
CN1107505C (zh) 2003-05-07
BG62612B1 (bg) 2000-03-31
LV12719A (lv) 2001-09-20
CZ290447B6 (cs) 2002-07-17
DE10199013I1 (de) 2001-05-23
DE122008000034I1 (de) 2008-10-02
HRP931102A2 (en) 1997-10-31
PT582455E (pt) 2001-03-30
LU90709I2 (fr) 2002-02-04
NL300032I1 (fi) 2001-02-01
SG52698A1 (en) 1998-09-28
WO1994003440A1 (en) 1994-02-17
RO113641B1 (ro) 1998-09-30
JPH06184124A (ja) 1994-07-05
ATE197295T1 (de) 2000-11-15
NZ255216A (en) 1996-05-28
LU91446I2 (fr) 2008-07-28
EP0582455B1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
NL300347I1 (nl) Benzoxazinonen als remmers van hiv omgekeerde transcriptase
ATE175412T1 (de) Hiv-protease-inhibitoren
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
DK0774969T3 (da) HIV-proteaseinhibitor kombination

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115457

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20050021

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: C20080013

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 264

Extension date: 20131120

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

Free format text: MERCK SHARP & DOHME CORP.

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: C20080013

MA Patent expired